Floatz logo

Capecitabine

Circulating Tumor Cell

Sixth Affiliated Hospital, Sun Yat-sen UniversitySmall moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
89/ 100

Competitive context

7 Active assets in the Circulating Tumor Cell cohort.

Asset / SponsorPhaseRating
Piritramide
The Institute of Molecular and Translational Medicine, Czech Republic
Phase 4BB
NEPENTHE
The Institute of Molecular and Translational Medicine, Czech Republic
Phase 4BB
Eloxatin
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3B
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
AC Camargo Cancer Center
Phase 2CCC
TRASTUZUMAB
AC Camargo Cancer Center
Phase 2CCC

View all 12 →

Same molecule, other indications

Capecitabine is also rated in:

Locally Advanced Rectal CancerDormant
BBB
Indicative ·
75 / 100
View asset →
colorectal neoplasmDormant
BBB
Indicative ·
74 / 100
View asset →
rectal carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →